How I'd Review an Article About GLP-1s: A Worked Example

The fastest way to explain what clinical content review involves is to do it. So here is a short passage of the kind I read most weeks — fluent, confident, and quietly unsafe. It is invented, deliberately, to be a fair composite rather than a caricature of any real article:

"Skinny jabs are the breakthrough everyone's been waiting for. Semaglutide melts away fat with virtually no effort — studies show users lose up to 15% of their body weight, and most people see results within weeks. It works by suppressing your appetite so you simply eat less. Best of all, it's safe and easy to start, with pens available online from a range of suppliers."

Four sentences. Nothing in them is illiterate, and a reader in a hurry might find them reassuring. Below is how each line reads to a clinician, what it gets wrong, and how it should have been written. The point is not to mock the passage. It is to make the invisible work of review visible.

Line one: the framing problem

"Skinny jabs are the breakthrough everyone's been waiting for."

The damage here is done before any fact is stated. "Skinny jab" frames a long-term medical treatment for a chronic condition as a cosmetic shortcut — an aesthetic fix rather than the management of a relapsing disease under clinical supervision. That framing shapes everything a reader does next: how seriously they take the risks, whether they think of stopping as relapse, whether they involve a clinician at all.

It should read something like: "GLP-1 receptor agonists such as semaglutide are licensed medicines used, under clinical supervision, to treat obesity as a chronic condition." Less exciting. Considerably more honest. The reframing is not cosmetic editing — it is the single most consequential change on the page.

Line two: overclaiming and the orphaned statistic

"Semaglutide melts away fat with virtually no effort — studies show users lose up to 15% of their body weight, and most people see results within weeks."

Three separate failures, stacked.

"Melts away fat with virtually no effort" is clinically misleading. These medicines work alongside dietary change, activity and clinical support — not instead of them — and "no effort" actively discourages the behaviours that make treatment work and protect muscle mass during weight loss.

"Studies show" is doing concealment. Which studies, in whom, over what period? The headline figures come from large randomised trials in defined populations over many months — not from "users" in the vague, testimonial sense the sentence implies. "Up to 15%" is the orphaned statistic: a best-case ceiling presented as a typical result, with no average, no range, and no denominator. A reader cannot tell whether it is what most people get or what the luckiest few achieved.

"Most people see results within weeks" compresses a months-long, dose-escalated treatment into a promise of speed — the sentence that sells, and the sentence that disappoints.

It should read: "In randomised trials, average weight loss with semaglutide was substantial over roughly a year of treatment, alongside lifestyle support; individual results vary, and the medicine is titrated up slowly over months." Specific, sourced in spirit, and honest about variation.

Line three: a correct mechanism, carelessly amputated

"It works by suppressing your appetite so you simply eat less."

This is the closest the passage comes to being right, which makes its omissions easy to miss. Appetite suppression is genuinely part of the mechanism — but so is slowed gastric emptying, and that slowed emptying is also why the commonest side effects are gastrointestinal. By giving the flattering half of the mechanism and dropping the rest, the sentence removes the natural place to explain that nausea, vomiting and other GI effects are common, expected, and the reason for slow dose escalation.

The word "simply" is the giveaway. Almost nothing about this is simple, and "simply" is doing reassurance the evidence does not support.

It should read: "It reduces appetite and slows stomach emptying, which is why it lowers food intake — and why gastrointestinal side effects such as nausea are common, particularly as the dose increases." The same fact, with the safety information welded back on where it belongs.

Line four: the sentence that would worry me most

"Best of all, it's safe and easy to start, with pens available online from a range of suppliers."

This is where I stop being an editor and start being a doctor.

"Safe" with no qualifier is indefensible for any medicine. GLP-1s have a real side-effect profile, recognised contraindications, populations in whom they should not be used, and rare but serious safety signals that warrant prompt medical attention. "Safe" erases all of it. The clinical edit is not to call the medicine dangerous — it is to replace a bare adjective with named, proportionate information and a clear route to a prescriber.

"Easy to start" misrepresents what starting actually involves: clinical assessment of suitability, screening for contraindications, dose titration, and follow-up. There is no safety-netting anywhere in the passage — not one line telling a reader which symptoms mean stop and seek medical advice today. For a class of medicine with recognised serious signals, that omission alone would fail the piece.

And then the quiet one: "pens available online from a range of suppliers." This is the most dangerous clause on the page precisely because it sounds like a convenience. It says nothing about the difference between a legitimately prescribed medicine and an unregulated product from an unverified source — and regulators have repeatedly warned about counterfeit GLP-1 pens reaching the public. A clinical review does not soften this sentence; it deletes the implied shopping route entirely.

It should read: "Like all medicines, GLP-1s carry risks as well as benefits, are not suitable for everyone, and require assessment and ongoing supervision by a qualified prescriber. Buying from unregulated online sources carries serious risks, including counterfeit products. Seek urgent medical advice if you develop severe or persistent abdominal pain, persistent vomiting, or signs of an allergic reaction." Three sentences the original could not bring itself to write.

What the exercise shows

Read the corrected versions back to back and a pattern emerges. Almost every edit is an addition — a named side effect, a denominator, a contraindication, a route to a clinician. The original was not full of false statements. It was full of true-ish statements with the safety-critical context edited out, wrapped in a cosmetic frame that told readers to take none of it seriously.

That is what clinical content review actually catches, and why it cannot be done by tidying the prose. The prose was fine. The medicine was the problem.

Practical takeaways

• The framing line does the most damage: "skinny jab" recasts a supervised treatment for a chronic condition as a cosmetic shortcut, and everything downstream inherits that error.
• "Studies show … up to 15%" is an orphaned best-case figure with no population, period, or average — the most common form of medication overclaiming.
• A half-told mechanism usually hides the safety information; the dropped half is where the side effects live.
• "Safe and easy to start, available online" is three failures in one clause — and the implied sourcing route is the line a reviewer deletes outright.
• Almost every clinical edit is an addition, not a correction — which is exactly why fixing the writing alone never makes the content safe.

What this doesn't mean

It doesn't mean GLP-1 medicines are bad, or that every enthusiastic article is reckless. These are genuinely important treatments for a serious chronic condition. The point is narrower: enthusiasm is not a substitute for safety information, and a passage can be readable, broadly accurate, and still fail the people most likely to act on it.

When to seek medical advice

GLP-1 medicines are prescription-only and should be started and monitored by a qualified prescriber who can assess your suitability. Never source them from unregulated online suppliers. If you are taking one and develop severe or persistent abdominal pain, persistent vomiting, or signs of an allergic reaction, seek urgent medical attention.

A closing thought

I did not have to call a single sentence in that passage a lie. That is the unsettling part. The most common failure in medication writing is not falsehood — it is true-sounding prose with the dangerous bits quietly removed, and you only notice what is missing if you already know it should be there.

Further reading and sources

• NICE — technology appraisals on GLP-1 receptor agonists for weight management (TA875, TA1026)
• MHRA — Drug Safety Updates and warnings on counterfeit GLP-1 pens
• British National Formulary (BNF) — GLP-1 receptor agonists: indications, cautions, interactions
• This site's companion pieces — How GLP-1 Medicines Actually Work and What GLP-1 Medicines Don't Do
• Patient Information Forum — PIF TICK criteria for trustworthy health information